Pharmaceuticals

With its Healthcare Services platform growing, SelectQuote executives will face investors to detail their tech-driven strategy amid market pressures.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

Neurizon Therapeutics has started dosing its promising ALS drug, NUZ-001, in the groundbreaking HEALEY Platform Trial, a pivotal step for patients.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

With clinical results converging, a new report reveals the real GLP-1 battle is fought in patent filings, not labs, deciding who wins this $100B+ market.

Amid new regulations, eClinical Solutions unveils agentic AI to automate data review, streamline compliance, and accelerate breakthrough therapies.

Biotech giant Regeneron extends its sponsorship of America's top high school science contest, securing its legacy and boosting access for a new generation.

A new partnership integrates massive clinical trial data with an AI design platform, promising to slash drug development timelines and costs. Here's how.

A new global alliance aims to solve the costly patient adherence problem by merging world-class marketing with a proven, AI-powered digital health platform.

Sarepta will unveil crucial long-term data for its Duchenne gene therapy and exon-skipping drugs at MDA 2026, a pivotal moment for patients and the company.

A key partnership ensures the supply of a breakthrough therapy for FOP, a devastating condition where muscle turns to bone, highlighting a new era in drug production.

With new strategic leaders from Roche and capital markets, GATC Health aims to embed its AI risk prediction tool into pharma R&D and biotech investing.

With the hire of Greg Crescenzi, the famed academic repository signals a major strategic expansion to bridge the gap between scientific sharing and drug development.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

With promising data for its oral STAT6 degrader and a cash runway into 2029, Kymera Therapeutics is poised to disrupt the injectable-dominated market.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

With record SUBLOCADE revenue and a new U.S. home, Indivior launches a $400M buyback, signaling a new era in its fight against the opioid crisis.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.

Perrigo takes a massive $1.3B impairment charge and plans a 7% workforce reduction as it pivots to a 'CORE' business amid a challenging outlook.